Bronchogen

Bronchogen
Identifiers
  • (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-4-carboxybutanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoic acid
CAS Number
PubChem CID
Chemical and physical data
FormulaC18H30N4O9
Molar mass446.457 g·mol−1
3D model (JSmol)
  • C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N
  • InChI=1S/C18H30N4O9/c1-8(2)6-12(18(30)31)22-17(29)11(7-14(25)26)21-16(28)10(4-5-13(23)24)20-15(27)9(3)19/h8-12H,4-7,19H2,1-3H3,(H,20,27)(H,21,28)(H,22,29)(H,23,24)(H,25,26)(H,30,31)/t9-,10-,11-,12-/m0/s1
  • Key:OFZRHTIWKZWPQF-BJDJZHNGSA-N

Bronchogen is a tetrapeptide with the sequence AEDL or Ala-Glu-Asp-Leu. It has antiinflammatory effects and is claimed to be of therapeutic effect in conditions involving inflammation of bronchial epithelial cells in the lungs, such as chronic obstructive pulmonary disease (COPD), although essentially all evidence for its efficacy is derived from Russian research using rats and mice rather than human clinical trials.

See also